
Opinion|Videos|November 25, 2024
Shared Decision-making for Selection of FDA-approved Therapies for NMOSD
Author(s)Michael Levy, MD, PhD
Key Takeaways
- Efficacy, safety, dosing frequency, and patient-specific factors are key in selecting NMOSD therapies.
- Eculizumab and ravulizumab may be preferred for patients with severe relapses or contraindications to B-cell depletion.
A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
- What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
- Discuss shared decision-making when managing patients with APQ4+ NMOSD.
Advertisement
Related to this article

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
3
From Glucose to Cognition: Where Repurposed Diabetes Drugs Stand in Alzheimer Disease
4
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
5


